ACTIVE_NOT_RECRUITING

Salt-Sensitivity and Immunity Cell Activation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events. The precise mechanisms of how dietary salt contributes to blood pressure elevation, renal injury, and cardiovascular disease remains unclear. Our data indicated that monocytes exhibit salt sensitivity, and the investigators hypothesize that of salt sensitivity of these and similar immune cells correlate with the hypertensive response to salt intake. Currently, the research tools for diagnosing salt-sensitivity are costly, time consuming and laborious. In this study the investigators will identify monocyte salt-sensitivity as a marker of salt-sensitive hypertension.

Official Title

Salt-Sensitivity and Immunity Cell Activation

Quick Facts

Study Start:2021-09-01
Study Completion:2026-09-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT03753204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * We will perform a pilot analysis in 20 hypertensive subjects controlled for gender (50% men, 50% women), age (18-60 years),
  2. * New or pre-existing diagnosis of essential hypertension defined as systolic blood pressure \>140 mmHg or \>90 mmHg diastolic or taking antihypertensive medications regardless of current blood pressure.
  3. * BMI (18.5-24.9).
  4. * Only subjects who give informed consent will be studied.
  1. * Acute cardiovascular event(s) within the previous 6 months
  2. * Claustrophobia precluding obtaining an MRI
  3. * Inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol.
  4. * Current excessive alcohol or illicit drug use.
  5. * Blood pressure below the inclusion criteria levels after discontinuation of therapy
  6. * Presence of metal implants such as artificial joints.
  7. * Concomitant diabetes mellitus, type I or II.
  8. * Autoimmune disease.
  9. * Recent vaccination
  10. * Younger or older that inclusion criteria.
  11. * Pregnancy.

Contacts and Locations

Principal Investigator

Annet Kirabo
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • Annet Kirabo, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-01
Study Completion Date2026-09-15

Study Record Updates

Study Start Date2021-09-01
Study Completion Date2026-09-15

Terms related to this study

Additional Relevant MeSH Terms

  • High Blood Pressure
  • Salt; Excess
  • Inflammation